Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Geron Corporation
GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in antineoplastic effects.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years of age or older
Male or female
Measurable or evaluable solid tumor malignancy
Relapsed, refractory, locally advanced, or metastatic disease
Disease refractory to or not amenable to standard therapy
Karnofsky performance status 70-100%
Life expectancy 3 months or greater
You may not be if
Pregnant or lactating women
Primary central nervous system(CNS) malignancy or active CNS metastases
Hematologic malignancy
Chemotherapy within 4 weeks prior to study
Mitomycin C, nitrosoureas within 6 weeks prior to study
High dose chemotherapy with stem cell support within 6 months prior to study
Signal transduction inhibitors, monoclonal antibodies, etc. within 4 weeks prior to study
Systemic hormonal therapy within 4 weeks prior to study
Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study
